Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 77533, held by InvaGen Pharmaceuticals. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 77533 (Terbinafine Hydrochloride), held by InvaGen Pharmaceuticals, was first approved by FDA on Jul 2, 2007, with 6 approved supplements and 0 published complete response letters.
Terbinafine tablets, USP are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE ยท tablet;oral | Terbinafine Hydrochloride | Discontinued |
| Sep 11, 2025 | Supplement 14Labeling ยท Standard review | Approved | None posted |
| Sep 11, 2025 | Supplement 17Labeling ยท Standard review | Approved | None posted |
| Jan 10, 2016 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Jan 10, 2016 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| Jul 12, 2012 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Sep 20, 2011 | Supplement 3Labeling | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters